Overview of Adrome

Quick Facts

Property	Description
Active ingredient	Carbazochrome
Form	Tablets, Solution for Injection
Pharmacological class	Systemic Hemostatic Agent
Common use	Control of capillary bleeding and hemorrhage
Origin	Synthetic derivative of Adrenaline

What Type of Medicine is Adrome and What is its Composition?

Adrome is a pharmaceutical preparation classified as a systemic hemostatic agent (B02BX02). Its core component, the active ingredient, is Carbazochrome, also known as Carbazocromo. This small molecule drug is a synthetic derivative originating from adrenaline (or its oxidation product, adrenochrome), and its specific chemical structure is adrenochrome monosemicarbazone. The medicine is designed as a single-ingredient product, containing only Carbazochrome (often prepared as Carbazochrome sodium sulfonate) as the therapeutic entity, affirming its classification as an antihemorrhagic agent.

How Does Carbazochrome Differ from Coagulation Factors?

The fundamental purpose of Carbazochrome is to manage bleeding by acting as a capillary stabilizer at the level of the microvasculature. It achieves this by increasing capillary resistance and enhancing the overall microcirculatory tone. This mechanism targets vascular integrity, distinguishing it from agents that directly initiate major blood clot formation. This action functions by reducing vessel permeability. Adrome specifically reinforces the walls of small blood vessels and inhibits vascular hyperpermeability. Its primary role is controlling localized bleeding, particularly associated with fragile capillary and parenchymal tissues.

What are the Available Drug Forms of Adrome?

Adrome is prepared in several distinct dosage forms that facilitate different routes of administration, a key feature for therapeutic flexibility. These forms commonly include tablets intended for oral administration and an aqueous vehicle solution contained in ampoules for parenteral routes, such as subcutaneous or intramuscular injection. The consistency of the active ingredient across these forms ensures that the core capillary stabilizing action of Carbazochrome can be delivered effectively, regardless of the physical preparation.

What side effects are possible with Adrome?

Possible Side Effects and Safety Information

The safety profile of Adrome (Carbazochrome) is officially documented by regulatory authorities, classifying possible adverse reactions primarily by frequency and the body system affected. These classifications establish the expected risk profile of the medicine during use, separating common, non-serious events from rare, clinically significant reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped according to their expected rate of occurrence, based on regulatory definitions:

Classification	Example Documented Effect(s)
Common	Nausea, Injection site reaction (with parenteral administration)
Uncommon	Headache, Dizziness, Gastrointestinal discomfort
Rare	Allergic skin reactions (e.g., rash, urticaria)
Very Rare	Anaphylactic reactions

System-Organ Classes and Serious Reactions

Official labeling groups effects under Gastrointestinal disorders, Nervous system disorders, and Immune system disorders. While common reactions are generally mild, the safety documentation explicitly notes the risk of Anaphylactic reactions in the Very Rare category. This reaction is a serious adverse event affecting the immune system.

Population and Temporal Safety Constraints

The regulatory profile establishes key constraints for use, including a contraindication for individuals with known hypersensitivity to Carbazochrome or its excipients. Additionally, the official label notes a temporal pattern, stating that allergic reactions, including the serious ones, are typically observed to occur shortly after administration. Precautionary use is generally advised for specific populations, such as during Pregnancy and Lactation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Adrome, which contains the active ingredient Carbazochrome (a systemic hemostatic agent), is primarily defined by the lack of known, specific toxicity and the mandated emergency response.

Feature	Official Regulatory Statement
Documented overdose presentations:	No specific, characteristic symptoms or clinical signs are formally documented in official labeling following an acute overdose event.
Physiological systems affected (as stated in label):	No specific physiological systems are officially listed as being predictably affected by overdose in the regulatory information.
Emergency-response statements (as written in official documents):	Management should consist of symptomatic and supportive treatment.
When immediate medical help is required (label-derived phrasing only):	Seek immediate medical attention or contact emergency services immediately upon any suspected overdose.

Official Overdose Statements

No specific antidote is known or formally documented for Adrome overdose in the regulatory prescribing information.
No specific symptoms or clinical signs following an acute overdose are formally documented in official government labeling.
Treatment should be symptomatic and supportive, including the maintenance of vital functions and close observation.
Immediate medical attention is required in all cases of suspected overdose, regardless of the presence of overt symptoms.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by the absence of specific, characteristic acute symptoms and the absence of a known antidote. Consequently, regulators mandate that immediate medical help must be sought in all suspected overdose cases. Management is officially described as being limited to symptomatic and supportive treatment, with hospital monitoring often required to facilitate this care and observe the patient's condition.

Therapeutic Uses of Adrome

What Adrome Treats: Main Uses and Benefits

The therapeutic role of Adrome is primarily centered on the short-term, symptomatic management of acute distress and anxiety, especially during episodic flare-ups or periods of increased functional strain. It provides support that helps ease the overall burden of symptoms associated with acute or episodic changes.

The approach is commonly used when supportive symptom management is appropriate and short-term symptomatic assistance is needed. This therapeutic approach is relevant in contexts marked by increased discomfort or tension. This supportive role contributes to maintaining a sense of stability when symptoms are more noticeable or during phases of increased distress or discomfort.

Adrome is commonly used to help with symptoms that interfere with daily functioning, including intense anxiety, nervousness, or restlessness, physical manifestations of distress such as muscle tension or rapid heartbeat, and sleep disturbance due to overwhelming worry. It assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Supports Symptomatic Discomfort

Regulatory References

NIH StatPearls on Generalized Anxiety Disorder

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Adrome (Carbazochrome)

The formal eligibility profile for Adrome (Carbazochrome) is structured by regulatory authorities based on definitive contraindications and specific population limitations.

Contraindications and High-Risk Restrictions

Use of Adrome is contraindicated in any individual with a known hypersensitivity or allergy to Carbazochrome or its components. Official labeling also advises caution for patients with a history of thrombotic events due to the drug’s potential influence on platelet function. Furthermore, conditional use applies to individuals with renal impairment, as the medicine is primarily eliminated via the kidneys, and dedicated safety data for this patient group is often limited.

Physiological State and Age-Related Rules

Adrome is generally not recommended for women who are pregnant or breastfeeding. This is due to a lack of established safety data—it often carries a Pregnancy Category N/A, and excretion into human milk is unknown, making use conditional on an essential need. The medicine is established for the Adult Population. However, safety and efficacy data for the Pediatric Population are often limited or based on extrapolation from adult dosing. A specific use profile for the Geriatric Population is typically not specifically established in official regulatory summaries.

What should I know about interactions with other medicines?

The official interaction profile for Adrome, which contains the active ingredient Carbazochrome, is defined by the information, or lack thereof, documented in major international government regulatory sources. As of current labeling, no specific drug-drug, drug-food, or drug-substance interaction patterns are formally detailed by major health authorities, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).

Documented Restrictions and Contraindications

The regulatory documentation does not list any specific medicinal products or product classes explicitly classified as contraindicated due to an interaction risk with Adrome. Furthermore, there are no formally documented restrictions or mandatory requirements for separating the administration of Adrome from other therapeutic agents, nor are there any specified limitations concerning co-administration with alcohol, food, or herbal products.

Pharmacokinetic and Mechanistic Basis

No specific pharmacokinetic mechanisms—such as interactions mediated by Cytochrome P450 (CYP) enzymes or drug transporters (like P-gp)—are formally described in the official labeling. Accordingly, the regulatory text does not identify substances that cause a significant alteration (increase or decrease) in the systemic exposure of Adrome, nor does it detail Adrome’s effect on the exposure of co-administered medicines. The profile also lacks population-specific interaction cautions.

Conclusion of Regulatory Profile

This status confirms that the official prescribing information does not contain formally classified interaction data, reflecting the drug’s current regulatory position.

Mechanism of Action

The mechanism of action for Carbazochrome is defined by its targeted effects on the microcirculation, leading to its distinct physiological effect via two distinct, yet complementary, mechanistic domains: the stabilization of the capillary wall and contribution to platelet activity.

Capillary Wall Stabilization and Permeability Control

This mechanism focuses on establishing the structural integrity of the microvasculature. Carbazochrome acts to inhibit specific signaling cascades, such as phosphoinositide hydrolysis in endothelial cells, which are known to increase vessel porosity. This action helps restore critical tight junctions (like VE-cadherin) between the cells, resulting in a significant decrease in vascular hyperpermeability and an increase in capillary resistance.

Modulation of Primary Hemostasis

A secondary mechanism involves the local contribution to platelet function. Carbazochrome acts as an agonist on alpha-adrenoreceptors on the platelet surface, initiating an internal Ca^2+ signaling cascade. This activity promotes platelet contraction and aggregation at the site of microvascular injury, providing primary hemostatic contribution that complements the stabilization of the capillary wall.

Dosage and Administration Information

How to Use Adrome: Official Administration Guidelines

The application of Adrome is strictly governed by official documentation detailing the procedural steps for this systemic hemostatic agent. The medicine is available in two approved configurations: an oral tablet or capsule and a solution for injection. These options define the available administration routes as oral or parenteral via subcutaneous or intramuscular injection.

Administration Scope

The official dosing schedule for approved courses, such as those used in certain hemostatic conditions, dictates a standard regimen of 10 mg, administered once daily. This establishes the consistent treatment frequency and intensity. Regarding timing, the administration is typically independent of specific food intake.

A critical procedural constraint applies to the injectable form, which must be administered exclusively via the subcutaneous or intramuscular route by a qualified professional. A primary population-specific instruction requires dosage consideration when prescribing to individuals with renal impairment. This procedural principle ensures that the standard regimen is adjusted based on specific physiological conditions.

Connection to the Overall Use Protocol

The adherence to these administration rules structures the use protocol, ensuring that the appropriate route (oral or parenteral) and the standardized 10 mg once-daily dose are maintained. These labeled instructions define the administrative structure of the drug, ensuring consistency with established standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adrome (Carbazochrome)

This overview summarizes the official research evidence and study landscape for Adrome (Carbazochrome), focusing only on the types of clinical evaluations conducted, the outcomes monitored, and the areas where scientific certainty remains low. This is a descriptive summary, not clinical advice.

Evidence for Use in Capillary Hemorrhage Control

Research has explored the agent's evaluation in various situations characterized by localized, minor bleeding, with studies focusing on the integrity of the microvasculature. The research base for this broad area primarily includes older clinical trials and descriptive studies that were conducted during periods where localized bleeding was observed. Findings from these studies describe patterns observed in relation to the microvasculature over the short-term. However, there is limited information for long-term outcomes, and the data relies heavily on studies that pre-date modern, high-quality placebo-controlled trial standards.

Evidence for Use in Orthopedic Surgery Blood Management

Adrome was evaluated in recent clinical research, primarily studied in adult patients undergoing major orthopedic procedures, such as Total Hip and Knee Arthroplasty. Studies monitored outcomes related to systemic or functional imbalance caused by blood loss. These findings describe patterns observed in these studies, where some reports indicated differences in the volume of blood loss recorded, particularly when the agent was used in combination with other supportive therapies. Follow-up durations were limited to the immediate recovery phase, meaning long-term effects are not fully established.

Evidence in Specific, High-Risk Bleeding Scenarios

Research has explored the use of Adrome in specific contexts, such as post-trauma settings and in efforts to prevent bleeding following complex gastrointestinal (GI) procedures. This evidence largely comes from retrospective cohort studies and observational settings. In research related to trauma-induced hemorrhage, reports did not describe a clear separation of outcomes regarding critical endpoints, such as mortality. For GI bleeding prevention, the findings were mixed, with some observational studies reporting no significant difference in outcomes compared to control groups. This highlights that certainty remains low for the study of Adrome in these specific high-risk scenarios, and the evidence quality varies across studies.

Key Studies & References ATC/DDD Index: B02BX - Other systemic hemostatics (WHO Collaborating Centre for Drug Statistics Methodology)

Frequently Asked Questions (FAQ)

Common questions about Adrome (FAQ)

Q: Can Adrome be taken with over-the-counter pain relievers like ibuprofen?

A: According to the official regulatory labeling, no specific drug-drug, drug-food, or drug-substance interaction patterns for Adrome have been formally detailed. Official sources currently do not list specific restrictions regarding co-administration with general over-the-counter pain relievers such as ibuprofen.

Q: Can Adrome be taken with common allergy medications?

A: Regulatory documentation does not list specific product classes, including common allergy medications, as explicitly restricted due to an interaction risk with Adrome. The regulatory documentation does not note any specific requirement for separating administration from these types of agents.

Q: Does Adrome interact with birth control pills?

A: The official prescribing information for Adrome does not formally classify or detail an interaction between the medicine and hormonal contraceptives. No specific warnings or restrictions regarding co-use are noted in the regulatory documents.

Q: Can Adrome interact with common herbal supplements like St. John's Wort?

A: The official regulatory profile does not contain specific data or documented restrictions concerning co-administration with herbal products. This means the official labeling does not specify restrictions for use alongside common supplements such as St. John's Wort.

Q: Does Adrome affect blood pressure or heart rate?

A: Official documents classify adverse reactions like dizziness and headache under Nervous System disorders. However, the official safety profile does not explicitly list effects on blood pressure or heart rate as documented common, uncommon, or rare adverse reactions.

Q: Is it true that Adrome can cause mood changes?

A: Official regulatory documents list effects such as dizziness and headache under Nervous System disorders. However, the official safety profile does not specifically list mood changes or other psychiatric effects as documented adverse reactions.

Q: How long does the effect of a single dose of Adrome last?

A: The standard regimen dictates a once-daily frequency for approved courses. While the specific clinical duration of action for a single dose is not typically detailed in the public regulatory label, the recommended dosing frequency is once daily, which guides the overall treatment schedule.

Q: Is Adrome generally considered safe for long-term use?

A: Official research summaries currently state that evidence on long-term effects is not fully established, and studies have often been limited to immediate recovery periods. Due to this, the long-term safety profile of Adrome is not fully defined in official research summaries.

Q: What specific warnings are listed on the official label for Adrome?

A: Official labeling contains several precautions, including a contraindication (strict prohibition) for individuals with a known hypersensitivity to the drug or its components. It also advises caution for patients with a history of thrombotic events, and its use requires special consideration in the patient group with renal impairment.

Q: Is the efficacy of Adrome consistent across different patient populations?

A: Research has primarily involved adult patients undergoing surgery. Reports note that findings regarding outcomes were mixed in specific high-risk scenarios, indicating research data varies across different patient contexts.

Q: What is the shelf life of Adrome, and how should it be stored?

A: Regulatory guidelines require Adrome to be stored at a controlled room temperature (typically 20 C to 25 C) and not frozen. The medicine must be kept in its original container, protected from light and moisture. The specific shelf life or expiration date is printed on the product packaging.

Q: Is Adrome considered a controlled substance or scheduled drug?

A: Adrome is categorized by the World Health Organization (WHO) as a systemic hemostatic agent. The medicine is not listed as a controlled or scheduled drug under major international governmental regulatory lists.

Q: Why is Adrome used instead of older medicines for the same condition?

A: Official documentation states that Adrome’s core purpose is to act as a capillary stabilizer by increasing capillary resistance. This mechanism focuses specifically on reinforcing small blood vessel walls, which officially distinguishes its function from agents that directly initiate major blood clot formation.

Q: What does 'contraindicated' mean when official documents mention Adrome?

A: When a medicine is contraindicated, it means the use of the drug is strictly forbidden for individuals who have a specified condition or characteristic. This applies to conditions such as a known hypersensitivity (allergy) to the drug's components, as specified in the official documentation.

Q: Does Adrome build up in your system over time?

A: Official regulatory labels note that the medicine is primarily eliminated via the kidneys. Because elimination is a key factor in systemic exposure, use requires special consideration for individuals with renal impairment.

Q: Does Adrome cause weight changes, and if so, what kind?

A: Weight changes are not listed as a common, uncommon, rare, or very rare adverse reaction in the official regulatory safety profile for Adrome.

Q: Is it normal to feel tired or drowsy when first starting Adrome?

A: Feeling tired or drowsy is not listed as a common, uncommon, rare, or very rare adverse reaction in the official regulatory safety profile for Adrome.

Q: How does Adrome affect sleeping patterns generally?

A: Effects on sleeping patterns or insomnia are not listed as a common, uncommon, rare, or very rare adverse reaction in the official regulatory safety profile for Adrome.

Q: Can people who are lactose intolerant use Adrome?

A: The specific inactive ingredients, known as excipients, can vary by product form (such as tablet or injection). Certain oral formulations of Carbazochrome, the active ingredient, may list Lactose Monohydrate as an inactive excipient. The presence of lactose depends on the specific product preparation.

Q: Can I use Adrome if I have a history of kidney problems?

A: Official documents state that conditional use applies to individuals with renal impairment. This is because the medicine is primarily eliminated via the kidneys, which means its use requires special consideration in this patient group.

Q: Are the reported side effects of Adrome usually temporary?

A: The regulatory profile specifically notes that allergic reactions, including serious ones, are typically observed to occur shortly after administration. A general statement on the temporary nature of all common side effects is not provided in the official labeling.

Q: How is Adrome typically eliminated from the body?

A: Official regulatory labels and monographs note that the medicine, or its active component Carbazochrome, is primarily eliminated via the kidneys.

Q: Are there different strengths or formulations of Adrome?

A: Adrome is approved in different preparations, including both an oral tablet/capsule form and a solution for injection. The standard regimen for approved courses often dictates a specific dose, such as 10 mg.

Q: Does drinking alcohol affect Adrome's effectiveness or safety?

A: The official interaction profile for Adrome does not specify any limitations concerning co-administration with alcohol. No restrictions are detailed in the official regulatory documents.

Q: What if I experience a rare or unexpected side effect from Adrome?

A: Government drug authorities, such as the FDA and MHRA, provide official systems for users to report side effects or unexpected events. This process helps these agencies monitor the safety profile of the medicine.

Q: Does Adrome cause sensitivity to the sun?

A: Sensitivity to the sun (photosensitivity) is not listed as a common, uncommon, rare, or very rare adverse reaction in the official regulatory safety profile for Adrome.

Q: Does Adrome have any effect on appetite?

A: Effects on appetite (increase or decrease) are not listed as a common, uncommon, rare, or very rare adverse reaction in the official regulatory safety profile for Adrome.

How should Adrome be stored and disposed of?

How to Store and Dispose of Adrome

Official regulatory guidelines define specific conditions for storing and disposing of Adrome (Carbazochrome) to maintain its stability.

Storage Requirements

Adrome must be stored at a controlled room temperature, typically between 20°C and 25°C, and it must not be frozen. The active ingredient requires protection from both light and moisture, meaning the medicine must be kept in its original, tightly closed container.

Child Safety

In compliance with general regulatory mandates, Adrome must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Adrome should be discarded via an official drug take-back program when available. If a program is not accessible, the product must be mixed with an undesirable substance and placed in a sealed container before disposal in the household trash, following the specific procedure mandated by the FDA. The product must not be flushed down drains or toilets.

Adrome